State of Michigan Retirement System Purchases New Shares in Enovis Co. (NYSE:ENOV)

State of Michigan Retirement System acquired a new position in Enovis Co. (NYSE:ENOVGet Rating) during the second quarter, HoldingsChannel reports. The fund acquired 12,002 shares of the company’s stock, valued at approximately $660,000.

Other large investors also recently made changes to their positions in the company. Cooke & Bieler LP bought a new position in shares of Enovis in the second quarter valued at about $86,274,000. DAVENPORT & Co LLC acquired a new position in shares of Enovis during the second quarter worth approximately $34,432,000. Royce & Associates LP bought a new stake in shares of Enovis during the second quarter valued at approximately $34,391,000. River Road Asset Management LLC acquired a new stake in shares of Enovis in the second quarter valued at approximately $15,827,000. Finally, Wedge Capital Management L L P NC bought a new position in Enovis in the 2nd quarter worth approximately $13,924,000. Institutional investors own 89.40% of the company’s stock.

Enovis Price Performance

Shares of NYSE:ENOV opened at $53.92 on Tuesday. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of 112.34, a P/E/G ratio of 1.18 and a beta of 2.03. The firm’s 50 day simple moving average is $49.33 and its 200 day simple moving average is $55.74. Enovis Co. has a fifty-two week low of $43.88 and a fifty-two week high of $157.71.

Analysts Set New Price Targets

ENOV has been the subject of several research reports. Canaccord Genuity Group initiated coverage on Enovis in a research note on Monday, September 12th. They issued a “buy” rating and a $67.00 target price for the company. TheStreet cut Enovis from a “c” rating to a “d” rating in a report on Wednesday, November 2nd. Jefferies Financial Group began coverage on shares of Enovis in a research report on Wednesday, October 12th. They set a “buy” rating and a $60.00 target price on the stock. Canaccord Genuity Group assumed coverage on shares of Enovis in a research note on Monday, September 12th. They set a “buy” rating and a $67.00 price target for the company. Finally, Evercore ISI started coverage on shares of Enovis in a research note on Monday, September 12th. They issued an “outperform” rating and a $68.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Enovis has an average rating of “Moderate Buy” and an average price target of $63.50.

Enovis Profile

(Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

Further Reading

Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Co. (NYSE:ENOVGet Rating).

Institutional Ownership by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.